Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
10.1016/j.regpep.2009.05.008 3 BarisicI.BalenovicD.KlicekR.RadicB.NikitovicB.DrmicD.et al (2013)
Because of the risk of serious adverse outcomes resulting from sedation and dissociation and respiratory depression caused by esketamine nasal spray administration, and the potential for abuse and misuse of the product, it is only available through a restricted distribution system under a Risk Evaluation and Mitigation Strategy (REMS)
Based on the claims data available for the CY 2023 OPPS/ASC final rule with comment period, we found the median was the statistical methodology that estimated the highest cost for the service
In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70334 through70336), in response to commenters' concerns regarding packaging payment for potentially high-cost surgical procedures into the payment for an observation C-APC, we finalized a policy that claims reporting procedures assigned status indicator T do not qualify for payment through C-APC 8011, regardless of whether the procedure assigned status indicator T was furnished before or after observation services (described by HCPCS code G0378) were provided
US$ 22.38
US$ 26.03
US$ 27.14
US$ 29.81
US$ 26.03
US$ 27.98
US$ 21.82
